Voyager Therapeutics, Inc. (VYGR)
Voyager Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Voyager Therapeutics, Inc. (VYGR) is a Biotechnology company based in US with a market capitalization of $189.7M. Revenue declined 49.5% year-over-year and free cash flow was negative at -$135.1M. This page tracks VYGR's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 172 employees · IPO Nov 11, 2015
Valuation
Valuation & price
$3.62as of Jul 7, 2026· -32.1% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
0.97
P/B ratio
Market cap ÷ book equity
No dividend
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$189.7M
Market cap
-49.5%
Revenue growth (YoY)
100.0%
Gross margin
-$135.1M
Free cash flow (USD)
-$159.9M
Net debt
Net cash position
1.8%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 7, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 13, 2026Filing
GLP Toxicology Data Presentation
- 8-K eventJun 10, 2026Filing
Authorized Shares Increase
- 8-K eventJun 1, 2026Filing
FDA Clearance
- Quarterly reportMay 7, 2026Filing
10-Q Filed
- 8-K eventMay 7, 2026Filing
Earnings Release
- 8-K eventApr 21, 2026Filing
CFO Resignation and Appointments
- Insider sellApr 3, 2026Filing
Insider Sell $45KSandrock Alfred · Director, President and CEO · $44.5K
Questions
Frequently asked questions
What is Voyager Therapeutics, Inc.'s market cap?
Voyager Therapeutics, Inc. (VYGR) has a market capitalization of $189.7M.
What is VYGR's P/E ratio?
A meaningful P/E ratio is not available for VYGR — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is VYGR's price-to-book (P/B) ratio?
VYGR trades at 0.97 times book value per share.
Does Voyager Therapeutics, Inc. pay a dividend?
No — VYGR did not pay a dividend in its latest reported fiscal year.
Are insiders buying VYGR stock?
SEC Form 4 filings show no open-market insider buys at Voyager Therapeutics, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.